Conclusions: The follow-up schedule for stage I should be different from that for the other stages. We recommend that intensive follow-up is appropriate in stage III CC patients with undifferentiated adenocarcinoma or N2 nodal status, stage II RC patients with high preoperative CEA level, and stage III RC patients.
INTRODUCTION
Colorectal cancer (CRC) is one of the most common malignancies worldwide [1] . CRC has been increasing annually in Japan, and was estimated to be the most common malignancy in 2016 and the second most common cause of cancer-related deaths in 2014 [2] .
The usefulness of intensive surveillance with routine carcinoembryonic antigen (CEA) monitoring and computed tomography (CT) scans remains controversial. Although early detection of recurrence has been shown to improve survival, early detection using intensive surveillance did not always result in improved overall survival [4] [5] [6] [7] [8] [9] . The guidelines of the Japanese Society for Cancer of the Colon and Rectum propose intensive surveillance, including CEA checks every 3 months and CT every 6 months for 3 years, regardless of clinical stage and risk of recurrence [10] . This reflects the intensive surveillance schedules recommended by the European Society for Medical Oncology, American Society of Clinical Oncology, and National Comprehensive Cancer Network (NCCN) guidelines, which recommended CEA checks every 3-6 months and CT every 6-12 months for 2-3 years, depending on the risk of the patient [11] [12] [13] [14] [15] .
However, these surveillances are not strictly categorized by risk factors other than clinical stage. Information on time to recurrence (TTR) and survival after recurrence (SAR) may help to determine the appropriate follow-up schedule, and has previously been used to evaluate the usefulness of intensive follow-up in clinical trials and meta-analysis [3, 5, 7, 8] .
In this study, we evaluated the clinicopathological factors predicting TTR and SAR in patients with colon cancer (CC) or rectal cancer (RC) during intensive follow-up after curative resection, to determine the factors influencing the appropriate follow-up schedule.
RESULTS

Differences in clinicopathological factors between CC and RC
We compared the clinicopathological factors between CC and RC (Table 1) . Age group, gender, preoperative CEA level, tumor depth, nodal status, venous invasion, application of adjuvant therapy, and clinical stage all differed significantly between the two locations.
Factors associated with recurrence
The recurrence rates of stages I, II, and III CC were 1.2% (11/890), 13 .1% (151/1149), and 26.3% (263/1000), and of RC were 8.4% (54/641), 20 .0% (123/614), and 30.4% (212/697), respectively (Table 1) . High preoperative CEA level, tumor depth, nodal status, lymphatic invasion, venous invasion, and clinical stage were significantly associated with recurrence, regardless of tumor location (Table 1) . Gender and histological type were significantly associated with recurrence in RC, but not in CC.
We also assessed the influence of tumor location on recurrence in relation to each clinicopathological factor (Table 1) . There were significant differences in recurrence rates between CC and RC for patients in each age group, with each CEA level, each histological type, and with tumor depth of T1-3, N0 nodal status, lymphatic invasion of ly0-2, venous invasion of v0-2, stage I-II and stage I-II without adjuvant therapy. However, there were no significant differences in recurrence rates by tumor location in relation to clinically-advanced factors including: depth of T4, N1 and N2 nodal status, lymphatic invasion of ly3, venous invasion of v3, and stage III.
Factors associated with RFS and OS
RFS was significantly influenced by preoperative CEA level, histological type, tumor depth, nodal status, stage, lymphatic invasion, and venous invasion, regardless of tumor location (Figures 1, 2) . RFS was also significantly influenced by gender in patients with RC ( Figure 2) . OS was significantly influenced by age, gender, preoperative CEA level, tumor depth, nodal status, stage, lymphatic invasion, and venous invasion, regardless of tumor location (Figures 3, 4) . OS was also significantly influenced by histological type in RC alone ( Figure 4 ).
Clinicopathological factors in patients with recurrence
Age group, gender, tumor depth, nodal status, stage, TTR, type of recurrence, and sites of recurrence differed significantly between CC and RC in patients with recurrence ( Table 2 ). The liver was the most common metastatic site in CC patients, followed by the lungs, peritoneum, and distant lymph nodes. In contrast, the lungs were the most common metastatic site in RC patients, followed by the liver, local recurrence, and distant lymph nodes. There was no significant difference in preoperative CEA, histological type, or treatment after recurrence according to tumor location.
Time to recurrence (TTR)
TTR was significantly longer in stage III patients with RC compared with CC patients, but not in stage I and II patients ( Figure 5A-5C ). The 1-, 2-, 3-, and 5-year accumulative recurrence rates in CC patients were 18%, 46%, 73%, and 91% for stage I; 46%, 78%, 90% and 99% for stage II; 53%, 80%, 94% and 97% for stage III, respectively ( Figure 5D ). The equivalent recurrence rates in RC patients were 17%, 41%, 65%, and 87% for stage I; 49%, 81%, 94%, and 98% for stage II; 44%, 71%, 83%, and 98% for stage III respectively ( Figure 5E ).
We further assessed TTR for CC and RC patients depending on stage, except for stage I, because there were fewer patients and longer TTR than for the other stages.
TTR in stage II CC was significantly associated with gender, preoperative CEA level, lymphatic www.oncotarget.com invasion, and distant lymph node metastasis (Table 3) . TTR in stage III CC was significantly associated with preoperative CEA level, lymphatic invasion, and venous invasion (Table 3 ). Multivariate analysis showed that high preoperative CEA level and lymphatic invasion were independent predictors for short TTR in both stage II and stage III CC (Table 4) . TTR in stage II RC was significantly associated with metastatic factors (liver metastasis and distant lymph node metastasis), but not pathological factors. TTR in stage III RC was significantly associated with both pathological factors (lymphatic invasion and vascular invasion) and metastatic factors (M1b recurrence and liver metastasis) ( Table 3 ). Multivariate analysis showed that venous invasion and liver metastasis were independent predictors for short TTR in stage III RC (Table 4) .
Survival after recurrence (SAR)
The 5-year survival rates after recurrence for CC and RC were 81% and 77% in stage I; 55% and 58% in stage II; 40% and 39% in stage III, respectively ( Figure  5F -5H). There were significant differences in the 5-year SAR rates among stages, but not between CC and RC ( Figure 5F -5J Subgroups were compared with log-rank test. P values were provided when differences were significant (P<0.05) and as NS when differences were not significant. Subgroups were compared with log-rank test. P values were provided when differences were significant (P<0.05) and as NS when differences were not significant. www.oncotarget.com Subgroups were compared with log-rank test. P values were provided when differences were significant (P<0.05) and as NS when differences were not significant. Subgroups were compared with log-rank test. P values were provided when differences were significant (P<0.05) and NS was used when differences were not significant. 
DISCUSSION
We evaluated the clinicopathological factors associated with TTR and SAR in patients with CC and RC, as critical factors for guiding appropriate followup after curative surgery [3] [4] [5] . Appropriate follow-up after curative surgery has been proposed by TTR or the accumulative recurrence rate, but not SAR.
The recurrence rate in this study (16.3%) was similar to those in previous studies [3, 7] . The recurrence rate in stage I CC patients was only 1.2%, so we excluded these patients from analysis of TTR and SAR. The recurrence rate in stage I RC patients was 8.4%, and the accumulative recurrence rates were 16.7% and 64.8% at 1 and 3 years, respectively. Therefore, stage I RC patients may require different surveillance from stage II and III patients. We also excluded stage I RC patients for further analysis of TTR and SAR.
Among stage II and III patients, the accumulative recurrence rate was about 50% at 1 year, which was higher than in some previous reports, but similar to that in the FACS trial involving intensive surveillance, including CT [3, 7] . The 2-and 3-year recurrence rates in patients with stages II and III were 70%-80% and 80%-90%, respectively. These are similar to the previous data by Kobayashi et al and suggest that intensive surveillance with CEA checks every 3 months are necessary for at least 3 years, in contrast to the NCCN recommendation of 2 years [3, 14, 15] . TTR differed significantly between CC and RC in stage III patients. Predictors for TTR were different between CC and RC. In CC, patients with high preoperative CEA level and lymphovascular invasion could be followed-up as candidates for early recurrence. On the other hand, predictors in RC were venous invasion and liver metastasis. Therefore, follow-up in RC should include CT to evaluate liver metastasis.
Our data showed that predictors for TTR were not prognostic factors for SAR. Short TTR has been previously reported to influence survival in small cases of study [16, 17] . In this study, recurrence within 1 year was an independent prognostic factor for poor SAR in stage III RC patients. Age (≥75), type of recurrence (M1b), and treatment after recurrence (surgical resection) were also identified as independent prognostic factors for SAR in the current study. Surgical resection was considered a strong prognostic factor for advanced CRC [18, 19] . Recent improvement of treatments against metastatic CRC may provide better SAR than that in current study [20, 21] .
Therefore, we proposed that patients with prognostic factors for poor SAR should receive intensive treatment and follow-up after curative surgery. These patients include stage III CC patients with undifferentiated adenocarcinoma or N2 nodal status, stage II RC patients with high preoperative CEA level, and stage III RC patients.
Our study had several limitations. First, it was a retrospective study, and we had no genetic information, Although it seems advisable to detect recurrence as soon as possible to improve the chances of curative resection, the usefulness of intensive follow-up remains controversial. Furthermore, it is unclear if early detection of recurrence could increase the rate of curative treatment and improve survival. Our data demonstrated that short TTR was an independent prognostic factor for SAR in stage III RC patients, who should have received intensive follow-up. However, further prospective studies are needed to confirm our results. Genetic assessment is indispensable in the era of molecular-targeted therapy.
MATERIALS AND METHODS
Patients and data collection
This retrospective multicenter study was conducted by the Japanese Study Group for Postoperative Followup of Colorectal Cancer (JFUP-CRC). Clinical data were collected for CRC patients who underwent curative surgery at 22 hospitals in Japan between 2007 and 2008. The study was approved by the institutional review board or ethics committee at each hospital and was performed according to the Declaration of Helsinki and Ethical Guidelines for Clinical Research. All patients provided written informed consent. The JFUP-CRC office pooled and prepared the data available for clinical study, as described in the 7 th edition of the Japanese Classification of Colorectal Carcinoma [23] . Lymphatic (ly) or venous (v) invasion was classified according to the degree of invasion, as follows: no invasion (ly0/v0), minimal invasion (ly1/v1), moderate invasion (ly2/v2), or severe invasion (ly3/v3). A total of 4992 CRC patients who underwent curative resection in 2007 and 2008, without preoperative chemotherapy/radiotherapy, hereditary CRC, lateral lymph node metastasis, or colitic cancer, were considered suitable for assessment. These patients usually received follow-up with CEA tests every 3 months and CT every 6 months for 3 years, and then CEA every 6 months and CT every 12 months for 3-5 years. The median follow-up time was 72 months in all patients and 60 months in patients with recurrence.
Data analysis
Differences in clinicopathological factors according to tumor location (CC or RC) were analyzed for all patients and for patients with recurrence. Factors associated with recurrence were assessed using χ 2 tests. The influences of clinicopathological factors on relapse-free survival (RFS) and overall survival (OS) in all patients, and TTR and SAR in patients with recurrence were assessed using log-rank tests. Prognostic factors associated with TTR and SAR were subjected to multivariate analyses using a Cox proportional hazard model or logistic analysis. A P value of <0.05 was considered significant for all analyses.
CONCLUSIONS
We recommend that intensive follow-up after surgery is appropriate in stage III CC patients with undifferentiated adenocarcinoma or N2 nodal status, stage II RC patients with high preoperative CEA level, and stage III RC patients. 
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